Drug Profile
Research programme: facioscapulohumeral muscular dystrophy therapeutics - Fred Hutchinson Cancer Research Center/GlaxoSmithKline
Alternative Names: DUX4 protein inhibitors - Fred Hutchinson Cancer Research Center/GlaxoSmithKline; FSHD therapeutics - Fred Hutchinson Cancer Research Center/GlaxoSmithKlineLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center; GlaxoSmithKline
- Developer Fred Hutchinson Cancer Research Center; GSK
- Class Small molecules
- Mechanism of Action DUX4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Facioscapulohumeral muscular dystrophy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Facioscapulohumeral muscular dystrophy in United Kingdom
- 16 Jul 2016 No recent reports of development identified for research development in Facioscapulohumeral muscular dystrophy in USA
- 10 Dec 2012 Early research in Facioscapulohumeral muscular dystrophy in United Kingdom (unspecified route)